But the place has the drug inventory decree gone? Three months after the publication of his study on drug shortages, UFC-Que Choisir waits, waits… however sees nothing coming! While the danger is nice that the inventory decree will merely fall into oblivion, I name on the authorities to pull itself collectively: the measure have to be carried out with out additional delay.
In phrases of drug stocks, the horizon appeared to have cleared up: in 2019, Edouard Philippe introduced bold measures to struggle recurring shortages. This need was adopted by parliamentarians in December 2019, inside the framework of the social safety financing invoice (PLFSS 2020), and a decree was to be rapidly printed. However, in 2021, it appears to have been postponed indefinitely.
This delay is insupportable, as the stakes are excessive: in 2020, 2,400 medicine had been affected by shortages. This is twice as a lot as in 2019 (1,200) and 6 occasions greater than in 2015 (391). Our examine famous the unacceptable penalties of those shortages for customers: much less appropriate therapeutic alternate options, difficulties in adapting to the new dosage and, in 18% of instances, a complete lack of resolution!
The lengthy-awaited decree was, nevertheless, removed from bold: solely two brief months of stocks when the UFC-Que Choisir, in addition to affected person associations, referred to as for the structure of stocks of at the very least 4 months for all medicine. main therapeutic curiosity. An affordable requirement to guarantee entry to remedy for all, after we know that the shortages final on common 14 weeks.
But then, what occurred to this textual content? The strain from industrialists is monumental: followers of simply-in-time manufacturing, and in the everlasting seek for the lowest value, they’re fiercely preventing in opposition to the structure of stocks, at each nationwide and European degree. Today blocked in Brussels (whose opinion is vital, due to the guidelines of the Single Market), the destiny of the decree arouses little consideration from the French authorities, which exhibits little inclination to defend it. The arguments in favor of the measure are, nevertheless, strong: French stocks are meant to be “rolling”, thus not main to elevated consumption or over-storage, and different European international locations already represent them (Finland and Netherlands).
While the pandemic has highlighted the fragility of the French well being system, I ask the authorities to lastly implement this measure supplied for by regulation. Users mustn’t bear the value of political procrastination and authorities complacency in the direction of the pharmaceutical trade any longer!
